<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18634" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bromocriptine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ozery</surname>
            <given-names>Matan</given-names>
          </name>
          <aff>Florida International University Herbert Wertheim College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matan Ozery declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18634.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bromocriptine, an ergot alkaloid derivative classified as a dopamine D2 agonist, is a medication&#x000a0;used to&#x000a0;manage type 2 diabetes, Parkinson disease, acromegaly, and pituitary prolactinomas.&#x000a0;Bromocriptine finds utility in off-label applications for peripartum cardiomyopathy and neuroleptic malignant syndrome.</p>
        <p>This activity focuses on elucidating the indications, contraindications, and mechanism of action of bromocriptine, emphasizing its dopaminergic contributions in therapeutic contexts. This activity&#x000a0;aims to enhance the understanding of interprofessional healthcare teams regarding the pharmacological effects, potential adverse events, and strategies of bromocriptine for optimizing therapeutic regimens.&#x000a0;This activity further enhances patient treatment standards and improves outcomes across diverse clinical settings by guiding informed decisions regarding the prescription of bromocriptine, optimizing dosage adjustments, and minimizing adverse effects within a dynamic clinical landscape.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for bromocriptine in managing type 2 diabetes, Parkinson disease, acromegaly, and pituitary prolactinomas.</p></list-item><list-item><p>Implement appropriate dosage adjustments for bromocriptine based on individual patient characteristics and therapeutic response.</p></list-item><list-item><p>Select bromocriptine as an appropriate treatment option based on patient-specific factors and clinical guidelines.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams to ensure coordinated care, optimize treatment, and adjust interventions as necessary.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18634&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18634">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18634.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bromocriptine is an ergot alkaloid derivative in the dopamine D2 agonist class of drugs used&#x000a0;to manage&#x000a0;various conditions, including type 2 diabetes, Parkinson disease, acromegaly, and pituitary prolactinomas.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p><bold>Type 2 diabetes:&#x000a0;</bold>The most recent FDA-approved indication for bromocriptine mesylate is as a supplemental medication for adults with type 2 diabetes to help with glycemic control.<xref ref-type="bibr" rid="article-18634.r1">[1]</xref>&#x000a0;Type 2 diabetes is a chronic metabolic disorder with a multifactorial pathogenesis, characterized by insulin resistance, pancreatic &#x003b2;-islet dysfunction, and numerous additional metabolic abnormalities.<xref ref-type="bibr" rid="article-18634.r2">[2]</xref>&#x000a0;This complexity often necessitates the use of combinations of medications that address the various aspects of the disease, making bromocriptine an appealing treatment option. A systematic review of 11 studies suggests that bromocriptine potentially improves insulin sensitivity in diabetes. It shows promise as an add-on to metformin but appears less effective than teneligliptin. Further research is needed to fully assess its efficacy in diabetes management.<xref ref-type="bibr" rid="article-18634.r3">[3]</xref>&#x000a0;The American Diabetes Association (ADA) 2024 guidelines consider bromocriptine as a therapeutic option for type 2 diabetes.<xref ref-type="bibr" rid="article-18634.r4">[4]</xref></p>
        <p><bold>Hyperprolactinemia:&#x000a0;</bold>Bromocriptine is an FDA-approved medication indicated for disorders causing hyperprolactinemia, which most often is due to the most common type of pituitary adenoma: prolactinoma.<xref ref-type="bibr" rid="article-18634.r5">[5]</xref><xref ref-type="bibr" rid="article-18634.r6">[6]</xref><xref ref-type="bibr" rid="article-18634.r7">[7]</xref>&#x000a0;Prolactinomas affect both men and women and often&#x000a0;cause sexual dysfunction, gonadal abnormalities, infertility, and headaches.<xref ref-type="bibr" rid="article-18634.r8">[8]</xref>&#x000a0;Before the development of dopamine agonists, surgery was the mainstay of the treatment of prolactinomas.<xref ref-type="bibr" rid="article-18634.r8">[8]</xref>&#x000a0;As the first dopamine agonist, bromocriptine is now the standard medical therapy. Surgery is reserved for severe cases where medical treatment has failed to reduce prolactin secretion or the adenoma has caused visual disturbances or neurological deficits.<xref ref-type="bibr" rid="article-18634.r8">[8]</xref></p>
        <p>The Pituitary Society's International consensus guidelines recommend dopamine agonist therapy for its effectiveness in lowering serum prolactin levels, improving the clinical consequences of hyperprolactinemia, and reducing adenoma size. Cabergoline is the preferred dopamine agonist for treating prolactin-secreting pituitary adenomas due to its long half-life, efficacy, and tolerability. Cabergoline is recommended for prolactinomas of Knosp grade greater than or equal to 2, while bromocriptine is used less frequently. Despite this, bromocriptine effectively reduces serum prolactin levels, increases testosterone, and restores sexual potency in men with chronic kidney disease and hyperprolactinemia.<xref ref-type="bibr" rid="article-18634.r9">[9]</xref></p>
        <p><bold>Acromegaly:&#x000a0;</bold>Acromegaly demonstrates a&#x000a0;characteristic set of complications associated with increased growth hormone&#x000a0;concentrations. Growth hormone levels are affected by the sympathetic nervous system, where the binding of catecholamines to &#x003b1;-receptors increases blood concentrations of growth hormone, while binding to &#x003b2;-receptors decreases them. In healthy adults, catecholamines (norepinephrine, epinephrine, and L-DOPA) increase blood concentrations of growth hormone.<xref ref-type="bibr" rid="article-18634.r10">[10]</xref>&#x000a0;However, in patients with acromegaly, sympathetic stimulation paradoxically decreases growth hormone levels, although the efficacy of this mechanism remains controversial.<xref ref-type="bibr" rid="article-18634.r10">[10]</xref><xref ref-type="bibr" rid="article-18634.r11">[11]</xref>&#x000a0;As a dopamine agonist, bromocriptine is FDA-approved for&#x000a0;treating&#x000a0;acromegaly.</p>
        <p><bold>Parkinson disease:&#x000a0;</bold>Parkinson disease is a progressive neurological disorder characterized by resting tremor, rigidity, akinesia or bradykinesia, and postural instability due to the loss of dopaminergic neurons in the substantia nigra.<xref ref-type="bibr" rid="article-18634.r12">[12]</xref>&#x000a0;Although levodopa effectively treats Parkinson disease, its efficacy and motor complications decrease with chronic use.<xref ref-type="bibr" rid="article-18634.r13">[13]</xref><xref ref-type="bibr" rid="article-18634.r14">[14]</xref>&#x000a0;In&#x000a0;cases where levodopa is no longer effective, coadministration with dopamine agonists such as bromocriptine was previously an effective option.<xref ref-type="bibr" rid="article-18634.r13">[13]</xref>&#x000a0;</p>
        <p>Bromocriptine is also used as an early treatment for Parkinson disease to delay the onset of the use of levodopa, ultimately delaying the likely dyskinesia and motor fluctuations associated with chronic levodopa therapy. However, with the development of newer non-ergot dopamine agonists, which offer equal or higher efficacy and a safer adverse effect profile, bromocriptine is no longer the drug of choice for many physicians despite the growing popularity of dopamine agonists.<xref ref-type="bibr" rid="article-18634.r15">[15]</xref><xref ref-type="bibr" rid="article-18634.r14">[14]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p><bold>Peripartum cardiomyopathy:&#x000a0;</bold>Bromocriptine&#x000a0;is used off-label for peripartum cardiomyopathy (PPCM)&#x000a0;in conjunction&#x000a0;with standard heart failure pharmacotherapy. Bromocriptine is a targeted treatment option in PPCM.<xref ref-type="bibr" rid="article-18634.r16">[16]</xref>&#x000a0;A meta-analysis demonstrated that adjunctive bromocriptine therapy, when added to standard guideline-directed medical therapy, significantly improved left ventricular ejection fraction and increased the likelihood of left ventricular recovery. However, this treatment regimen did not result in a statistically significant reduction in all-cause mortality.<xref ref-type="bibr" rid="article-18634.r17">[17]</xref>&#x000a0;Administering bromocriptine to postpartum patients should be approached cautiously due to reported severe and life-threatening adverse reactions, such as myocardial infarction, seizures, and stroke.</p>
        <p><bold>Neuroleptic malignant syndrome:&#x000a0;</bold>Bromocriptine is used in the management of neuroleptic malignant syndrome by restoring dopaminergic activity.<xref ref-type="bibr" rid="article-18634.r18">[18]</xref><xref ref-type="bibr" rid="article-18634.r19">[19]</xref></p>
      </sec>
      <sec id="article-18634.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bromocriptine is a dopamine receptor agonist with selective agonist activity on D2 dopamine receptors while simultaneously acting as a partial antagonist for D1 dopamine receptors.<xref ref-type="bibr" rid="article-18634.r20">[20]</xref>&#x000a0;Dopamine agonism has variable effects depending on the target tissue. In Parkinson disease, bromocriptine binds directly to striatal dopamine D2 receptors, stimulating locomotion and attenuating the bradykinetic symptoms caused by the degeneration of dopaminergic nigrostriatal neurons.<xref ref-type="bibr" rid="article-18634.r21">[21]</xref><xref ref-type="bibr" rid="article-18634.r13">[13]</xref>&#x000a0;Similarly, this agonistic effect on the D2 receptors of anterior pituitary lactotrophic cells inhibits prolactin exocytosis and gene expression, thereby reducing the adverse effects of hyperprolactinemia, particularly in the case of pituitary prolactinoma.</p>
        <p>In acromegaly, bromocriptine&#x02019;s dopaminergic effect can cause paradoxical blocking of growth hormone release through tuberoinfundibular pathways, decreasing circulating blood concentrations of growth hormone.<xref ref-type="bibr" rid="article-18634.r22">[22]</xref><xref ref-type="bibr" rid="article-18634.r10">[10]</xref> In type 2 diabetes, bromocriptine alters monoamine neurotransmitter concentrations in the suprachiasmatic and ventromedial nuclei of the hypothalamus, causing a sympatholytic effect that decreases metabolic processes, which can lead to glucose intolerance and insulin resistance.<xref ref-type="bibr" rid="article-18634.r2">[2]</xref>&#x000a0;Additionally, bromocriptine inhibits prolactin release from lactotroph cells in the anterior pituitary gland, reducing circulating prolactin levels and diminishing the formation of the 16-kDa prolactin isoform implicated in PPCM. By&#x000a0;reducing&#x000a0;prolactin signaling, bromocriptine&#x000a0;interrupts the&#x000a0;pathological cascade underlying PPCM.<xref ref-type="bibr" rid="article-18634.r16">[16]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Following administration of bromocriptine, peak plasma concentrations are typically reached within approximately 2.5 &#x000b1; 2 hours, with an elimination half-life of approximately 4.85 hours. Food intake does not notably affect the systemic exposure of bromocriptine; nevertheless, it is advisable to take bromocriptine with food to mitigate the risk of vomiting that may occur when administered on an empty stomach.</p>
        <p><bold>Distribution:</bold>&#x000a0;Bromocriptine exhibits high plasma protein binding, typically ranging from 90% to 96%, and primarily binds to serum albumin.&#x000a0;</p>
        <p><bold>Metabolism:</bold> Bromocriptine has a high affinity for CYP3A, with hydrolysis being the primary metabolic pathway. Consequently, inhibitors or potent substrates for CYP3A4 may inhibit bromocriptine clearance, leading to increased plasma levels. Additionally, bromocriptine acts as an inhibitor of CYP3A4. Bromocriptine undergoes extensive first-pass biotransformation.<xref ref-type="bibr" rid="article-18634.r20">[20]</xref></p>
        <p><bold>Elimination:</bold> Bromocriptine is primarily excreted in the bile, with approximately 2% to 6% excreted via the urine.<xref ref-type="bibr" rid="article-18634.r23">[23]</xref></p>
      </sec>
      <sec id="article-18634.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Bromocriptine is available in&#x000a0;2 forms, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>An oral tablet or capsule form (2.5-5.0 mg) for the treatment of hyperprolactinemia, acromegaly, and Parkinson&#x000a0;disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An oral tablet or capsule form (0.8 mg) for the treatment of type 2 diabetes.<xref ref-type="bibr" rid="article-18634.r24">[24]</xref><xref ref-type="bibr" rid="article-18634.r25">[25]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The standard release formulation (2.5-5 mg) reaches peak blood concentrations after approximately 3 hours with a bioavailability of 28%, while&#x000a0;the 0.8 mg formulation is&#x000a0;released more quickly and achieves peak blood concentrations within 45 to 60 minutes, with a bioavailability of 65% to 95%.<xref ref-type="bibr" rid="article-18634.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p>Treatment for the following disorders must be individualized based on a patient's unique characteristics. However, the recommended dosages for the following conditions are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hyperprolactinemia</bold>: An initial dosage of 1.25 to 2.50 mg daily, which may be increased to a maximum maintenance dosage of 5 mg daily.<xref ref-type="bibr" rid="article-18634.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acromegaly</bold>: An initial dosage of 1.25 to 2.50 mg daily, with incremental increases of 2.50 mg until desired growth hormone blood concentrations are achieved. Maintenance dosages typically range from 7.50 to 30.0 mg daily.<xref ref-type="bibr" rid="article-18634.r11">[11]</xref><xref ref-type="bibr" rid="article-18634.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Parkinson disease:</bold> The initial dosage is typically 2.50 mg daily, with increments of 2.50 mg based on tolerance and effectiveness. The goal is to use the lowest effective dose to achieve symptomatic control. A low dose is considered to be less than 30 mg daily, while a high dose ranges from 31 to 100 mg daily.<xref ref-type="bibr" rid="article-18634.r25">[25]</xref><xref ref-type="bibr" rid="article-18634.r13">[13]</xref><xref ref-type="bibr" rid="article-18634.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type 2 diabetes:</bold>&#x000a0;The initial dosage of 0.8 mg daily, with weekly increments of 0.8 mg until the desired level of glycemic control is achieved or up to a maximum dosage of 4.80 mg daily.<xref ref-type="bibr" rid="article-18634.r25">[25]</xref><xref ref-type="bibr" rid="article-18634.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> As the liver primarily metabolizes bromocriptine, caution should be exercised when administering it to patients with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;As only a small portion (6%) of bromocriptine is excreted by the kidneys, renal impairment may not substantially impact its pharmacokinetics.</p>
        <p><bold>Pregnancy considerations: </bold>Bromocriptine is not recommended during pregnancy and should be discontinued upon confirmation of pregnancy. If there is a need to resume bromocriptine to manage a rapidly expanding macroadenoma during pregnancy, the decision should be made cautiously, weighing the benefits against potential risks, including the risk of hypertensive disorder.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Bromocriptine is generally not recommended during breastfeeding due to its lactation-suppressing effects. In some cases, a daily dose of 2.5 mg for 3 days has been utilized to reduce excessive milk production. Although the drug is undetectable in breast milk at this dosage and adverse reactions have not been reported, the safety of this practice is not fully established. Cases of mothers successfully breastfeeding&#x000a0;while being treated with bromocriptine for amenorrhea-galactorrhea syndrome or prolactinoma during pregnancy and lactation have been documented.</p>
        <p>Bromocriptine has also been used to manage persistent galactorrhea following breast augmentation surgery and hyperprolactinemia and galactorrhea caused by antipsychotic medications.&#x000a0;The American Academy of Breastfeeding Medicine outlines the dopamine agonists&#x000a0;indicated for treating galactorrhea&#x000a0;that persists despite other interventions. While cabergoline is preferred&#x000a0;for its favorable adverse effect profile, bromocriptine serves as an alternative if cabergoline is unavailable. However, the use of bromocriptine for lactation suppression is discouraged due to the elevated risk of maternal stroke, seizures, cardiovascular disorders, death, and potentially psychosis.<xref ref-type="bibr" rid="article-18634.r27">[27]</xref><xref ref-type="bibr" rid="article-18634.r28">[28]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Although bromocriptine's safety and efficacy in treating prolactin-secreting pituitary adenomas have been established, its safety and effectiveness for other indications in the pediatric population have not been established.</p>
        <p><bold>Older patients:</bold>&#x000a0;Dopamine agonists, such as bromocriptine, should be used&#x000a0;cautiously in older adults due to the increased risk of cognitive impairment, psychosis, and impulse control disorders.<xref ref-type="bibr" rid="article-18634.r29">[29]</xref></p>
      </sec>
      <sec id="article-18634.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Adverse Effects</bold>
</p>
        <p>Common adverse effects of bromocriptine include nausea, vomiting, dizziness, hypotension, headache, and fatigue.<xref ref-type="bibr" rid="article-18634.r30">[30]</xref><xref ref-type="bibr" rid="article-18634.r31">[31]</xref><xref ref-type="bibr" rid="article-18634.r24">[24]</xref></p>
        <p>
<bold>Severe Adverse&#x000a0;Effects</bold>
</p>
        <p>Severe adverse effects of bromocriptine may include psychosis, fibrosis such as retroperitoneal, pleural, or cardiac valve fibrosis, and cardiovascular incidents, including valvular damage, stroke, and myocardial infarction.<xref ref-type="bibr" rid="article-18634.r31">[31]</xref><xref ref-type="bibr" rid="article-18634.r24">[24]</xref><xref ref-type="bibr" rid="article-18634.r32">[32]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bromocriptine binds strongly to serum proteins, potentially increasing the unbound fraction of other protein-bound medications such as salicylates, sulfonamides, and probenecid. This alteration may affect their effectiveness and risk of adverse effects.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dopamine receptor antagonists such as phenothiazines and metoclopramide can lessen bromocriptine's effectiveness and vice versa. Thus, concurrent&#x000a0;administration is not recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrently administering bromocriptine with ergot-related drugs may heighten ergot-related adverse effects. Therefore, bromocriptine and ergot-related medications should not be administered within 6 hours of each other.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension and tachycardia may occur when bromocriptine is coadministered with sympathomimetic drugs in postpartum women. Therefore, concurrent administration should be avoided.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Limited data suggest avoiding the concurrent use of selective 5-hydroxytryptamine 1B (5-HT1B) agonists (eg, sumatriptan) and bromocriptine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bromocriptine is metabolized by CYP3A4. Potent&#x000a0;CYP3A4 inhibitors, such as azole antimycotics and HIV protease inhibitors, or&#x000a0;CYP3A4 inducers, can affect&#x000a0;bromocriptine levels.<xref ref-type="bibr" rid="article-18634.r23">[23]</xref><xref ref-type="bibr" rid="article-18634.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18634.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Bromocriptine is contraindicated in patients with type 1 diabetes, syncope, and psychosis. Additionally, patients with syncopal migraines should avoid bromocriptine due to its potential to trigger hypotensive episodes. Breastfeeding individuals should also avoid bromocriptine because of its inhibitory effect on lactation.<xref ref-type="bibr" rid="article-18634.r23">[23]</xref>&#x000a0;Additionally, bromocriptine is metabolized by CYP450 3A4 and should not be used concurrently with CYP3A4 inhibitors or inducers or in patients with hepatic impairment.<xref ref-type="bibr" rid="article-18634.r23">[23]</xref><xref ref-type="bibr" rid="article-18634.r25">[25]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Hypotension</bold>: Orthostatic hypotension, including syncope, may occur&#x000a0;during bromocriptine therapy, particularly during initiation and dose escalation. Additionally, it is recommended to monitor orthostatic vital signs and exercise caution in patients on antihypertensive medications.</p>
        <p><bold>Psychotic disorders</bold>: Bromocriptine treatment may worsen severe psychotic disorders or reduce the effectiveness of concurrent antipsychotic medications; therefore, its use in patients with these conditions is not recommended.</p>
        <p><bold>Impulse control disorders:</bold>&#x000a0;Patients taking bromocriptine may experience intense urges such as pathological gambling, compulsive shopping, or hypersexuality. These urges may be resolved with dosage adjustment or discontinuation of the medication.<xref ref-type="bibr" rid="article-18634.r33">[33]</xref></p>
      </sec>
      <sec id="article-18634.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients using bromocriptine should take a pregnancy test if amenorrhea occurs due to the possibility of pregnancy and the risk of reduced fetal prolactin secretion with continued bromocriptine use. Bromocriptine should be discontinued if pregnancy is confirmed unless otherwise recommended by a physician.<xref ref-type="bibr" rid="article-18634.r34">[34]</xref></p>
        <p>Patients taking bromocriptine should also receive regular liver function test monitoring for elevated liver enzymes and&#x000a0;should undergo a cardiovascular assessment before using the drug.<xref ref-type="bibr" rid="article-18634.r25">[25]</xref><xref ref-type="bibr" rid="article-18634.r31">[31]</xref></p>
      </sec>
      <sec id="article-18634.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Bromocriptine is primarily metabolized in the liver via cytochrome P450 3A4 enzymes and is contraindicated in patients with hepatic impairment.<xref ref-type="bibr" rid="article-18634.r25">[25]</xref>&#x000a0;Accidental overdoses, particularly in children, have been reported and are characterized by dopaminergic effects, most notably hypotension.&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Treatment of bromocriptine overdose involves administering activated charcoal to prevent systemic absorption and magnesium citrate via a nasogastric tube, along with intravenous saline to increase blood pressure.<xref ref-type="bibr" rid="article-18634.r35">[35]</xref></p>
      </sec>
      <sec id="article-18634.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and treatment of complicated disorders such as type 2 diabetes, acromegaly, hyperprolactinemia, and Parkinson disease require not only a patient-centered approach but also an interprofessional team of healthcare workers who can guide patients from their first clinic visit until symptomatic control is achieved. When clinicians, nurses, pharmacists, laboratory technologists, medical students, and all other involved members of the healthcare team collaborate effectively, there is greater access to care, increased coordination of services, better outcomes in chronic disease, and improvements in patient safety.<xref ref-type="bibr" rid="article-18634.r36">[36]</xref><xref ref-type="bibr" rid="article-18634.r37">[37]</xref>&#x000a0;Lapses in interprofessional communication can cause confusion and mistakes with potentially lethal consequences.&#x000a0;</p>
        <p>The initial diagnosis involves collaboration between the primary care provider and the specialist. For correct dosage and administration, the clinician should consult with the pharmacist, and the pharmacist should communicate with the patient to ensure understanding of all instructions and potential adverse effects. If the patient incorrectly takes this medication, they should go to the emergency department, where nurses will be responsible for monitoring and consulting with toxicologists, radiologists, or pediatric specialists in the case of an accidental overdose in a child. If medical students are involved, they must effectively communicate with the attending physician, nurses, and technologists. Medical students trained in interprofessional education demonstrate more respect and positive attitudes when working with each other and other healthcare team members.<xref ref-type="bibr" rid="article-18634.r38">[38]</xref></p>
        <p>Patients with type 2 diabetes are assisted by Certified Diabetes Educators (CDEs) who provide nutritional guidance, in addition to mental health professionals, podiatrists, optometrists, and other community health workers who address the various sequelae associated with this condition. The formulation of bromocriptine used for diabetes is not indicated for other conditions. Patients with Parkinson disease, acromegaly, and hyperprolactinemia require continuous care from their respective neurological and endocrine teams.</p>
        <p>Bromocriptine&#x000a0;has a favorable adverse effect profile and rare severe adverse effects, but communication between&#x000a0;team members is necessary&#x000a0;to ensure safe and effective treatment. An interprofessional team approach and open communication between clinicians, pharmacists, nurses, and specialists are necessary to&#x000a0;optimize patient outcomes with bromocriptine&#x000a0;therapy.</p>
      </sec>
      <sec id="article-18634.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18634&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18634">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18634/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18634">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18634.s11">
        <title>References</title>
        <ref id="article-18634.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahajan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>197</fpage>
            <page-range>197-8</page-range>
            <pub-id pub-id-type="pmid">20523873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Defronzo</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-94</page-range>
            <pub-id pub-id-type="pmid">21447659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adusumilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hari Narayanan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gutlapalli</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Kheyson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bibawy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Otterbeck</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Efficacy of Bromocriptine as a Therapeutic Modality in the Treatment of Diabetes Mellitus: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>e41931</fpage>
            <pub-id pub-id-type="pmid">37588318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association Professional Practice Committee</collab>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.</article-title>
            <source>Diabetes Care</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>47</volume>
            <issue>Suppl 1</issue>
            <fpage>S158</fpage>
            <page-range>S158-S178</page-range>
            <pub-id pub-id-type="pmid">38078590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cugati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Hyperprolactinemia: An often missed cause of male infertility.</article-title>
            <source>J Hum Reprod Sci</source>
            <year>2011</year>
            <month>May</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-3</page-range>
            <pub-id pub-id-type="pmid">22065670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Pituitary Adenomas: A Review.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Feb</month>
            <day>07</day>
            <volume>317</volume>
            <issue>5</issue>
            <fpage>516</fpage>
            <page-range>516-524</page-range>
            <pub-id pub-id-type="pmid">28170483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casanueva</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kleinberg</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Montori</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wass</surname>
                <given-names>JA</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-88</page-range>
            <pub-id pub-id-type="pmid">21296991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colao</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pituitary tumours: the prolactinoma.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>575</fpage>
            <page-range>575-96</page-range>
            <pub-id pub-id-type="pmid">19945024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersenn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fleseriu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casanueva</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Giustina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biermasz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Biller</surname>
                <given-names>BMK</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chanson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gadelha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greenman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gurnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>KKY</given-names>
              </name>
              <name>
                <surname>Honegger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ioachimescu</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>Karavitaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Katznelson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lodish</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maiter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Molitch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Neggers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pivonello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Raverot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salvatori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shimon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Spencer-Segal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vila</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Melmed</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>722</fpage>
            <page-range>722-740</page-range>
            <pub-id pub-id-type="pmid">37670148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorner</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Chait</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mortimer</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Besser</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine treatment of acromegaly.</article-title>
            <source>Br Med J</source>
            <year>1975</year>
            <month>Feb</month>
            <day>08</day>
            <volume>1</volume>
            <issue>5953</issue>
            <fpage>299</fpage>
            <page-range>299-303</page-range>
            <pub-id pub-id-type="pmid">1111790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mashiter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Joplin</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine treatment of acromegaly.</article-title>
            <source>Metabolism</source>
            <year>1977</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>539</fpage>
            <page-range>539-46</page-range>
            <pub-id pub-id-type="pmid">576725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's disease: clinical features and diagnosis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>368</fpage>
            <page-range>368-76</page-range>
            <pub-id pub-id-type="pmid">18344392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine in Parkinson disease.</article-title>
            <source>Pharmacol Rev</source>
            <year>1985</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-27</page-range>
            <pub-id pub-id-type="pmid">3901046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stowe</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Ives</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Hilten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hawker</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Dopamine agonist therapy in early Parkinson's disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2008</year>
            <month>Apr</month>
            <day>16</day>
            <issue>2</issue>
            <fpage>CD006564</fpage>
            <pub-id pub-id-type="pmid">18425954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brooks</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Dopamine agonists: their role in the treatment of Parkinson's disease.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>685</fpage>
            <page-range>685-9</page-range>
            <pub-id pub-id-type="pmid">10811688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kryczka</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Demkow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dzieli&#x00144;ska</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers in Peripartum Cardiomyopathy-What We Know and What Is Still to Be Found.</article-title>
            <source>Biomolecules</source>
            <year>2024</year>
            <month>Jan</month>
            <day>12</day>
            <volume>14</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38254703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ravi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sivakumar</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Chidambaram</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Majella</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Al'Aref</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Asnani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis.</article-title>
            <source>Curr Probl Cardiol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>101461</fpage>
            <pub-id pub-id-type="pmid">36261102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barahona-Corr&#x000ea;a</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Oliveira-Maia</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Jun</month>
            <day>17</day>
            <volume>12</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31213433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pileggi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic Malignant Syndrome.</article-title>
            <source>Ann Pharmacother</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>11</issue>
            <fpage>973</fpage>
            <page-range>973-981</page-range>
            <pub-id pub-id-type="pmid">27423483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Bromocriptine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hisahara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shimohama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dopamine receptors and Parkinson's disease.</article-title>
            <source>Int J Med Chem</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>403039</fpage>
            <pub-id pub-id-type="pmid">25954517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dinan</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Prolactin and dopamine: what is the connection? A review article.</article-title>
            <source>J Psychopharmacol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>2 Suppl</issue>
            <fpage>12</fpage>
            <page-range>12-9</page-range>
            <pub-id pub-id-type="pmid">18477617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shivaprasad</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine in type 2 diabetes mellitus.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>Suppl 1</issue>
            <fpage>S17</fpage>
            <page-range>S17-24</page-range>
            <pub-id pub-id-type="pmid">21847449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Via</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Potenza</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Skamagas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2010</year>
            <month>Mar</month>
            <day>26</day>
            <volume>3</volume>
            <fpage>43</fpage>
            <page-range>43-8</page-range>
            <pub-id pub-id-type="pmid">21437075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holt</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine: old drug, new formulation and new indication.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>1048</fpage>
            <page-range>1048-57</page-range>
            <pub-id pub-id-type="pmid">20977575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhelst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abs</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hyperprolactinemia: pathophysiology and management.</article-title>
            <source>Treat Endocrinol</source>
            <year>2003</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-32</page-range>
            <pub-id pub-id-type="pmid">15871552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <chapter-title>Bromocriptine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Eglash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Leeper</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smillie</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Moore-Ostby</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>L</given-names>
              </name>
              <collab>Academy of Breastfeeding Medicine</collab>
            </person-group>
            <article-title>ABM Clinical Protocol #32: Management of Hyperlactation.</article-title>
            <source>Breastfeed Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>129</fpage>
            <page-range>129-134</page-range>
            <pub-id pub-id-type="pmid">32031417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latt</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zekry</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>VSC</given-names>
              </name>
            </person-group>
            <article-title>Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.</article-title>
            <source>Drugs Aging</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-202</page-range>
            <pub-id pub-id-type="pmid">30623310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Sarno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Leo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mentone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.</article-title>
            <source>Nat Clin Pract Endocrinol Metab</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>200</fpage>
            <page-range>200-10</page-range>
            <pub-id pub-id-type="pmid">16932285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weil</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The safety of bromocriptine in long-term use: a review of the literature.</article-title>
            <source>Curr Med Res Opin</source>
            <year>1986</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-51</page-range>
            <pub-id pub-id-type="pmid">3516579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanettini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gatto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tesei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pezzoli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Valvular heart disease and the use of dopamine agonists for Parkinson's disease.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Jan</month>
            <day>04</day>
            <volume>356</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">17202454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamidianjahromi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tritos</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>1089</fpage>
            <page-range>1089-1099</page-range>
            <pub-id pub-id-type="pmid">36125673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krupp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monka</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bromocriptine in pregnancy: safety aspects.</article-title>
            <source>Klin Wochenschr</source>
            <year>1987</year>
            <month>Sep</month>
            <day>01</day>
            <volume>65</volume>
            <issue>17</issue>
            <fpage>823</fpage>
            <page-range>823-7</page-range>
            <pub-id pub-id-type="pmid">3657044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermund</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Atwood</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Accidental bromocriptine ingestion in childhood.</article-title>
            <source>J Pediatr</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>105</volume>
            <issue>5</issue>
            <fpage>838</fpage>
            <page-range>838-40</page-range>
            <pub-id pub-id-type="pmid">6502320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemieux-Charles</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>What do we know about health care team effectiveness? A review of the literature.</article-title>
            <source>Med Care Res Rev</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-300</page-range>
            <pub-id pub-id-type="pmid">16651394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional collaboration in research, education, and clinical practice: working together for a better future.</article-title>
            <source>J Chiropr Educ</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">25594446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18634.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bridges</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Odegard</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Tomkowiak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional collaboration: three best practice models of interprofessional education.</article-title>
            <source>Med Educ Online</source>
            <year>2011</year>
            <month>Apr</month>
            <day>08</day>
            <volume>16</volume>
            <pub-id pub-id-type="pmid">21519399</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
